Skip to main content

Table 2 Treatment-emergent adverse events occurring in ≥30% of patients treated with MK-2206 plus trastuzumab ( n= 31)

From: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Adverse event All grades (%) Grade 3 (%) Grade 4 (%)
Fatigue 71.0 0 0
Hyperglycemia 51.8 6.5 0
Rash 58.1 16.7 0
Nausea 48.4 0 0
Alkaline phosphatase increase 45.2 6.5 0
Aspartate aminotransferase increase 45.2 9.7 0
Decreased appetite 41.9 0 0
Diarrhea 35.5 0 0
Alanine aminotransferase increase 32.3 3.2 3.2
Decreased hemoglobin 32.3 3.2 0
Dyspepsia 32.3 0 0
Hypoalbuminenia 32.3 0 0
Vomiting 32.3 0 0